PL318381A1 - Derivatives of aryloxy- and arylothiopropanoloamine useful as agonists of beta3-adrenoreceptor and antagonists of beta1 and beta2 adrenoreceptors and their pharmaceutic composition - Google Patents

Derivatives of aryloxy- and arylothiopropanoloamine useful as agonists of beta3-adrenoreceptor and antagonists of beta1 and beta2 adrenoreceptors and their pharmaceutic composition

Info

Publication number
PL318381A1
PL318381A1 PL95318381A PL31838195A PL318381A1 PL 318381 A1 PL318381 A1 PL 318381A1 PL 95318381 A PL95318381 A PL 95318381A PL 31838195 A PL31838195 A PL 31838195A PL 318381 A1 PL318381 A1 PL 318381A1
Authority
PL
Poland
Prior art keywords
arylothiopropanoloamine
adrenoreceptors
beta3
beta1
adrenoreceptor
Prior art date
Application number
PL95318381A
Other languages
English (en)
Inventor
Lee James Beeley
Mervyn Thompson
David Kenneth Dean
Nikesh Rasiklal Kotecha
John Michael Berge
Robert William Ward
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9415304A external-priority patent/GB9415304D0/en
Priority claimed from GB9423179A external-priority patent/GB9423179D0/en
Priority claimed from GBGB9510485.7A external-priority patent/GB9510485D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of PL318381A1 publication Critical patent/PL318381A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/30Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
    • C07F9/32Esters thereof
    • C07F9/3205Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/3211Esters of acyclic saturated acids which can have further substituents on alkyl
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/28Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines
    • C07C217/30Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring
    • C07C217/32Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
    • C07C217/34Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted by halogen atoms, by trihalomethyl, nitro or nitroso groups, or by singly-bound oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/30Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
    • C07F9/301Acyclic saturated acids which can have further substituents on alkyl
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/30Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
    • C07F9/303Cycloaliphatic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/30Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
    • C07F9/32Esters thereof
    • C07F9/3205Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/3223Esters of cycloaliphatic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40Esters thereof
    • C07F9/4003Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4006Esters of acyclic acids which can have further substituents on alkyl
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL95318381A 1994-07-29 1995-07-27 Derivatives of aryloxy- and arylothiopropanoloamine useful as agonists of beta3-adrenoreceptor and antagonists of beta1 and beta2 adrenoreceptors and their pharmaceutic composition PL318381A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9415304A GB9415304D0 (en) 1994-07-29 1994-07-29 Novel compounds
GB9423179A GB9423179D0 (en) 1994-11-17 1994-11-17 Novel compounds
GBGB9510485.7A GB9510485D0 (en) 1995-05-24 1995-05-24 Novel compounds

Publications (1)

Publication Number Publication Date
PL318381A1 true PL318381A1 (en) 1997-06-09

Family

ID=27267307

Family Applications (1)

Application Number Title Priority Date Filing Date
PL95318381A PL318381A1 (en) 1994-07-29 1995-07-27 Derivatives of aryloxy- and arylothiopropanoloamine useful as agonists of beta3-adrenoreceptor and antagonists of beta1 and beta2 adrenoreceptors and their pharmaceutic composition

Country Status (12)

Country Link
EP (1) EP0772585A1 (cs)
JP (1) JPH10503507A (cs)
CN (1) CN1159797A (cs)
AU (1) AU3254695A (cs)
BR (1) BR9508991A (cs)
CA (1) CA2196193A1 (cs)
CZ (1) CZ25597A3 (cs)
HU (1) HUT76800A (cs)
MX (1) MX9700765A (cs)
NO (1) NO970372L (cs)
PL (1) PL318381A1 (cs)
WO (1) WO1996004233A1 (cs)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9605495D0 (en) * 1996-03-15 1996-05-15 Smithkline Beecham Plc Novel compounds
US5914339A (en) * 1996-05-14 1999-06-22 American Home Products Corporation Substituted 1,3-benzodioxoles
EP0827746B1 (en) 1996-09-05 2002-04-03 Eli Lilly And Company Carbazole analogues as selective beta3 adrenergic agonists
WO1998022480A1 (en) * 1996-11-18 1998-05-28 Smithkline Beecham Plc Phosphorus containing aryloxy or arylthio propanolamine derivatives
GB9703492D0 (en) * 1997-02-20 1997-04-09 Smithkline Beecham Plc Novel compounds
CO5011072A1 (es) 1997-12-05 2001-02-28 Lilly Co Eli Etanolaminas pirazinil substituidas como agfonistas de los receptores
DE69928185T2 (de) * 1998-01-30 2006-07-20 Boulder Scientific Co., Mead Synthese von n-silylierten verbindungen
US6495546B1 (en) 1998-04-06 2002-12-17 Fujisawa Pharmaceutical Co., Ltd. Propanolamine derivatives
AUPP549998A0 (en) * 1998-08-26 1998-09-17 Fujisawa Pharmaceutical Co., Ltd. New compound
US7098248B2 (en) 2001-07-09 2006-08-29 Research Development Foundation Beta-adrenergic blockade reversal of catabolism after severe burn
DE102008064003A1 (de) * 2008-12-19 2010-06-24 Clariant International Limited Verfahren zur Herstellung von mono-funktionalisierten Dialkylphosphinsäuren, -estern und -salzen und ihre Verwendung
CN107266341B (zh) * 2017-06-23 2020-01-07 华东师范大学 芳氧基取代丙-2-醇胺的衍生物作为β3肾上腺素能受体拮抗剂、制备方法和用途
CN112442167A (zh) * 2019-08-28 2021-03-05 广东广山新材料股份有限公司 一种反应型阻燃剂及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1262729A (en) * 1983-10-19 1989-11-07 Leo Alig Phenoxypropanolamines
EP0300290B1 (de) * 1987-07-21 1991-12-18 F. Hoffmann-La Roche Ag Phenoxypropanolamine
GB8801306D0 (en) * 1988-01-21 1988-02-17 Ici Plc Chemical compounds
GB9215844D0 (en) * 1992-07-25 1992-09-09 Smithkline Beecham Plc Novel compounds

Also Published As

Publication number Publication date
CZ25597A3 (cs) 1998-02-18
AU3254695A (en) 1996-03-04
NO970372L (no) 1997-03-18
EP0772585A1 (en) 1997-05-14
HUT76800A (en) 1997-11-28
CA2196193A1 (en) 1996-02-15
NO970372D0 (no) 1997-01-28
WO1996004233A1 (en) 1996-02-15
JPH10503507A (ja) 1998-03-31
MX9700765A (es) 1997-05-31
BR9508991A (pt) 1997-10-21
CN1159797A (zh) 1997-09-17

Similar Documents

Publication Publication Date Title
HUP0101275A3 (en) Amide derivatives and pharmaceutical compositions containing them as nociceptin antagonists
HUP0001640A3 (en) N6 heterocyclic substituted adenosine derivatives, their use for production of pharmaceutical compositions and pharmaceutical compositions containing them
IL122345A0 (en) Benzamide derivatives their use as vasopressin antagonists processes for the preparation thereof and pharmaceutical compositions containing the same
IL112558A (en) Neuroprotective pharmaceutical compositions of 4 phenylpinene derivatives and certain novel 4 phenylpinene compounds
HUP0004150A3 (en) Indazole derivatives as tyrosine kinase receptor antagonists and pharmaceutical compositions containing them
HUP0005001A3 (en) Pyrrolidine derivatives as ep 4 receptor selective agonists and pharmaceutical compositions containing them
SG47877A1 (en) Use of tetrahydrocarbazone derivatives as 5HT receptor agonists
HUP9901296A3 (en) Substituted piperidine derivatives as nmda receptor antagonists and pharmaceutical compositions containing them
SI1475377T1 (sl) Indolni derivati in njihova uporaba kot inhibitorji fosfodiesteraze 4
IL116957A0 (en) Substituted heterocyclic compounds their preparation and pharmaceutical compositions containing them
IL112249A0 (en) Heterocyclic pyrimidine derivatives and pharmaceutical compositions containing them
PL318381A1 (en) Derivatives of aryloxy- and arylothiopropanoloamine useful as agonists of beta3-adrenoreceptor and antagonists of beta1 and beta2 adrenoreceptors and their pharmaceutic composition
HU9800291D0 (en) Use of amido-pirimidine derivatives for producing pharmaceutical compositions for inhibiting decrease of glucose-metabolismus
HUP0101688A3 (en) Heterocyclically substituted amides and their use for producing pharmaceutical compositions
PL331562A1 (en) Derivatives of tetraquinoline as antagonists of eaa
PL338004A1 (en) Derivatives of azetidinylpropylpiperidine, intermediate compounds and application of such derivatives as antagonists of tachykinins
PL340282A1 (en) Novel derivatives of cyclopentene useful as antagonists of motilin receptor
HUP9902026A3 (en) Use of bicyclic 4-aralkylaminopyrimidine derivatives for producing pharmaceutical compositions having tyrosine kinase inhibitor effect, novel bicicyclic 4-aralkylaminopirimidine derivatives and pharmaceutical compositions containing them
SG43951A1 (en) Use of indole derivatives as 5HT1 antagonists
HUP0004142A3 (en) Carboxamide derivatives as 5-ht1f agonists and pharmaceutical compositions containing them
PL335905A1 (en) Novel derivatives of pyridine and pharmaceutic compositions containing them
PL316757A1 (en) Benzamide derivatives and composition containing them as well as their application
HUP0102025A3 (en) Derivatives of 1,3,4-oxadiazolone, pharmaceutical compositions containing them and their use
IL114534A (en) Heterocyclic derivatives of azolones their preparation and pharmaceutical compositions containing them
PL330708A1 (en) Derivatives of indolydine useful as antagonists of 5-ht-2c receptor